8-KOther Events

QUEST DIAGNOSTICS INC 8-K Report (Apr 22, 2004)

Filed April 22, 2004For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed a Form 8-K on April 22, 2004, primarily to disclose its financial results for the quarter ended March 31, 2004, through an attached press release. This filing provides investors with timely information regarding the company's performance. The press release, incorporated by reference, is the key component of this report, offering details on the company's operational and financial condition as of that date. Investors should review the press release for specific financial metrics and any forward-looking statements made by Quest Diagnostics. This 8-K serves as an official channel for disseminating material information, ensuring compliance with Regulation FD and providing stakeholders with essential updates on the company's recent business activities and financial standing.

Key Highlights

  • 1Filing reports on Quest Diagnostics Incorporated's financial results for the quarter ended March 31, 2004.
  • 2The primary disclosure mechanism is a press release dated April 22, 2004, attached as Exhibit 99.1.
  • 3This 8-K filing is made pursuant to Regulation FD, ensuring fair disclosure of material information.
  • 4The report includes the company's state of incorporation (Delaware) and its IRS Employer Identification Number.
  • 5Robert A. Hagemann, Senior Vice President and Chief Financial Officer, signed the report on behalf of the company.
  • 6Item 7.c. and Item 9 are the relevant sections for financial statements/exhibits and Regulation FD disclosure, respectively.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce and disclose Quest Diagnostics Incorporated's financial results for the first quarter ended March 31, 2004, via an attached press release, in compliance with Regulation FD.

The specific financial details and results for the quarter ended March 31, 2004, are contained within the press release dated April 22, 2004, which is attached as Exhibit 99.1 to this 8-K filing.

The report is signed by Robert A. Hagemann, Senior Vice President and Chief Financial Officer of Quest Diagnostics Incorporated.

While the 8-K itself does not detail specific guidance, the attached press release (Exhibit 99.1) likely contains financial results and may include forward-looking statements or guidance from the company. Investors should refer to the press release for this information.